entertainment -WSS

entertainment

author：hotspot 2025-08-23 06:45:26 - browse：4555

a stethoscope and money – hospitals and health insurance coverage from STAT — Bright Health is officially leaving the health insurance market. The company has agreed to sell its Medicare Advantage plans to Molina Healthcare. Adobe

Bright Health Group has agreed to sell its Medicare Advantage plans to its publicly traded peer Molina Healthcare.

Regulators must approve the deal. But the pending sale of its Medicare Advantage business means the financially distressed Bright has exited the health insurance market that the company was founded on. It will solely operate roughly 70 physician clinics located in California, Texas, and Florida.

Molina agreed to pay $600 million for Bright’s 125,000 California Medicare Advantage enrollees, which equates to about $4,800 for each person. The federal government paid insurance companies almost $12,000, on average, for each MA enrollee in 2022. Molina said in a news release that Bright’s current book of business generates $1.8 billion of revenue, or more than $14,000 for each member.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

knowledge

WSS

Traditional Chinese medicine benefits explored in new JAMA study

Nobel honors Karikó and Weissman's enduring partnership

WHO recommends second malaria vaccine

Meta's Zuckerberg and Chan on track to put $50 billion into science

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Biden's order seeks to regulate AI risk without stifling innovation

hotspot

entertainment

focus

Drug repurposing or repositioning? The language matters

The Karikó problem: Lessons for funding basic research

Drug repurposing or repositioning? The language matters

Paying for Covid pills will soon shift to insurers

Virginia high school admissions case could be legal follow

6 solutions to address cancer drug shortages and others

The cancer drug shortage isn’t new — and neither are the solutions

Testing for cancer recurrence creates a new limbo for patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cassava reveals details — and problems — with Alzheimer's study

entertainment

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

6 solutions to address cancer drug shortages and others

Biden's order seeks to regulate AI risk without stifling innovation

Will an HIV vaccine ever be a reality?

6 solutions to address cancer drug shortages and others

Why Sanofi got shellacked over its spinoff

knowledge

explore

focus

hotspot